Venus Remedies: Health boost
The pharma manufacturer, which has registered steady growth and profits, is well-placed to capitalise on the growing market at home and abroad
We had written about Venus Remedies in the Street Beat section of our issue dated 15 July 2010. The stock was trading at around Rs268 at that time. It went up to a high of Rs327 and is now trading at around the same levels as last year, but is still a good buy.
The company is engaged mainly in manufacturing intravenous (I/V) fluids & injectables, ceftazidime, amlodipine, gliclazide and lisinopril. Its units are at Panchkula and Baddi (India)...
To continue reading this article, you must be a Premium subscriber...
More in Moneylife
TODAY'S TOP STORIES
Ameet Patel on Budget 2014
What's your say?
What you said
Thanks for casting your votes! View Previous Polls